However, unlike reports in patients heavily exposed to cytotoxic agents, we did not see a predominance of TP53 and PPM1D mutations expand, likely reflecting the unique plasma cell–directed mechanism of action of most agents employed in the treatment of multiple myeloma (18, 44). The gene discussed is TP53; the disease is AL amyloidosis.